Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats

S A van Nimwegen; R C Bakker; J Kirpensteijn; R J J van Es; R Koole; M G E H Lam; J W Hesselink; J F W Nijsen

doi:10.1111/vco.12319

Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats

S A van Nimwegen, R C Bakker, J Kirpensteijn, R J J van Es, R Koole, M G E H Lam, J W Hesselink, J F W Nijsen

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

BACKGROUND & AIMS: A "microbrachytherapy" was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 ( (166) Ho) microspheres (MS). (166) Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues.

MATERIALS & METHODS: Safety and efficacy of (166) Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis.

RESULTS: Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection. Median survival time was 113 days overall, and 296 days for patients with local response. Side effects were minimal. Tumour volume was a significant predictor of response.

DISCUSSION: Response rate may be further improved by optimizing the intratumoral spatial distribution of (166) Ho MS.

CONCLUSION: (166) Ho microbrachytherapy has potential as a minimally invasive, single procedure radio-ablation treatment of unresectable tumours with minimal morbidity.

Original language	English
Pages (from-to)	114-124
Number of pages	11
Journal	Veterinary and comparative oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1111/vco.12319
Publication status	Published - Mar 2018

Keywords

brachytherapy
feline
head and neck
holmium
radionuclide
tongue
translational model
tumour

Access to Document

10.1111/vco.12319

nimwegenFinal published version, 3.27 MB

Cite this

@article{f9ed00cba2094fada2a3a67ca4e85408,

title = "Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats",

abstract = "BACKGROUND & AIMS: A {"}microbrachytherapy{"} was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 ( (166) Ho) microspheres (MS). (166) Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues.MATERIALS & METHODS: Safety and efficacy of (166) Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis.RESULTS: Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection. Median survival time was 113 days overall, and 296 days for patients with local response. Side effects were minimal. Tumour volume was a significant predictor of response.DISCUSSION: Response rate may be further improved by optimizing the intratumoral spatial distribution of (166) Ho MS.CONCLUSION: (166) Ho microbrachytherapy has potential as a minimally invasive, single procedure radio-ablation treatment of unresectable tumours with minimal morbidity.",

keywords = "brachytherapy, feline, head and neck, holmium, radionuclide, tongue, translational model, tumour",

author = "{van Nimwegen}, {S A} and Bakker, {R C} and J Kirpensteijn and {van Es}, {R J J} and R Koole and Lam, {M G E H} and Hesselink, {J W} and Nijsen, {J F W}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.",

year = "2018",

month = mar,

doi = "10.1111/vco.12319",

language = "English",

volume = "16",

pages = "114--124",

number = "1",

}

TY - JOUR

T1 - Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats

AU - van Nimwegen, S A

AU - Bakker, R C

AU - Kirpensteijn, J

AU - van Es, R J J

AU - Koole, R

AU - Lam, M G E H

AU - Hesselink, J W

AU - Nijsen, J F W

PY - 2018/3

Y1 - 2018/3

N2 - BACKGROUND & AIMS: A "microbrachytherapy" was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 ( (166) Ho) microspheres (MS). (166) Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues.MATERIALS & METHODS: Safety and efficacy of (166) Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis.RESULTS: Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection. Median survival time was 113 days overall, and 296 days for patients with local response. Side effects were minimal. Tumour volume was a significant predictor of response.DISCUSSION: Response rate may be further improved by optimizing the intratumoral spatial distribution of (166) Ho MS.CONCLUSION: (166) Ho microbrachytherapy has potential as a minimally invasive, single procedure radio-ablation treatment of unresectable tumours with minimal morbidity.

AB - BACKGROUND & AIMS: A "microbrachytherapy" was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 ( (166) Ho) microspheres (MS). (166) Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues.MATERIALS & METHODS: Safety and efficacy of (166) Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis.RESULTS: Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection. Median survival time was 113 days overall, and 296 days for patients with local response. Side effects were minimal. Tumour volume was a significant predictor of response.DISCUSSION: Response rate may be further improved by optimizing the intratumoral spatial distribution of (166) Ho MS.CONCLUSION: (166) Ho microbrachytherapy has potential as a minimally invasive, single procedure radio-ablation treatment of unresectable tumours with minimal morbidity.

KW - brachytherapy

KW - feline

KW - head and neck

KW - holmium

KW - radionuclide

KW - tongue

KW - translational model

KW - tumour

U2 - 10.1111/vco.12319

DO - 10.1111/vco.12319

M3 - Article

C2 - 28480610

SN - 1476-5810

VL - 16

SP - 114

EP - 124

JO - Veterinary and comparative oncology

JF - Veterinary and comparative oncology

IS - 1

ER -

Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats

Abstract

Keywords

Access to Document

Fingerprint

Cite this